At the 2025 J.P. Morgan Healthcare Conference held recently, now in its 43rd year, South Korea-based Lotte Biologics unveiled the company's innovative proprietary antibody-drug conjugate (ADC) platform, SoluFlex Link, and announced plans to collaborate with drug product partners in North America to provide a comprehensive one-stop ADC service.

SoluFlex Link is a proprietary ADC platform featuring a linker technology jointly developed by Lotte Biologics and Kanaph Therapeutics, a biotech venture specialising in drug-conjugation technology. SoluFlex Link overcomes the major challenge of instability in ADC therapeutics.

Its flexible design supports compatibility with a wide range of antibodies and payloads, empowering ADC developers to innovate with diverse applications. Additionally, the platform is engineered to boost both production efficiency and therapeutic performance, positioning it as an ideal solution for next-generation ADC development and manufacturing.

Looking ahead to 2030, the company is constructing three advanced bio plants in Songdo, South Korea. With construction of the first plant already underway and expected to be operational by 2027, each facility will feature eight 15,000L stainless steel bioreactors for large-scale commercial production, along with multiple 2,000L single-use bioreactors to meet clinical production needs. Collectively, these plants will provide a manufacturing volume exceeding 360,000L in bioreactor capacity.